Lilly Ends Basal Insulin Peglispro Development Program By: Benzinga via Benzinga December 04, 2015 at 08:00 AM EST Eli Lilly and Company (NYSE: LLY) today announced that it will cease development of basal insulin peglispro (BIL), a potential treatment ... Read More >> Related Stocks: Eli Lilly